References
- Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997;28:652–9.
- Yao H, Yuzuriha T, Koga H, Fukuda K, Endo K, Matsumoto T, . Decreased plasma tryptophan associated with deep white matter lesions in elderly subjects. J Neurol Neurosurg Psychiatry. 1999;66:100–3.
- Gouw AA, van der Flier WM, Fazekas F, van Straaten EC, Pantoni L, Poggesi A, . Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the leukoaraiosis and disability study. Stroke. 2008;39:1414–20.
- Hara K, Shiga A, Fukutake T, Nozaki H, Miyashita A, Yokoseki A, . Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med. 2009;360:1729–39.
- Markus HS. Unravelling the genetics of ischaemic stroke. PLoS Med. 2010;7(3):e1000225.
- Oka C, Tsujimoto R, Kajikawa M, Koshiba-Takeuchi K, Ina J, Yano M, . HtrA1 serine protease inhibits signaling mediated by Tgfbeta family proteins. Development. 2004;131:1041–53.
- Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest. 2003;112:1342–50.
- Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515–81.
- Goumans MJ, Liu Z, ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res. 2009;19:116–27.
- Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000;1:169–78.
- Gordon KJ, Blobe GC. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta. 2008;1782:197–228.
- Kuriyama N, Mizuno T, Ohshima Y, Yamada K, Ozaki E, Shigeta M, . Intracranial deep white matter lesions (DWLs) are associated with chronic kidney disease (CKD) and cognitive impairment: a 5-year follow-up magnetic resonance imaging (MRI) study. Arch Gerontol Geriatr. 2013;56:55–60.
- Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, . Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41.
- Fisher CM. Lacunes: small, deep cerebral infarcts. Neurology. 1965;15:774–84.
- Jungreis CA, Kanal E, Hirsch WL, Martinez AJ, Moossy J. Normal perivascular spaces mimicking lacunar infarction MR imaging. Radiology. 1988;169:101–4.
- Kuriyama N, Mizuno T, Kita M, Nagakane Y, Hosomi A, Harada S, . Predictive markers of blood cytokine and chemokine in recurrent brain infarction. J Interferon Cytokine Res. 2009;29:729–34.
- Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, . Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43:1683–9.
- de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, Jolles J, . Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol. 2000;47:145–51.
- Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74.
- Pepper MS. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 1997;8:21–43.
- Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, . TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med. 2001;7:612–8.
- Yadav H, Quijano C, Kamaraju AK, Gavrilova O, Malek R, Chen W, . Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. Cell Metab. 2011;14:67–79.
- Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342:1350–8.
- Gelb BD. Marfan's syndrome and related disorders — more tightly connected than we thought. N Engl J Med. 2006;355:841–4.
- Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol. 2007;22:2011–22.
- Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis. 2005;12:353–65.
- Pratt B, Curci J. Arterial elastic fiber structure. Function and potential roles in acute aortic dissection. J Cardiovasc Surg. 2010;51:647–56.
- Muscogiuri G, Sorice GP, Tripathy D, Chavez AO, Davalli A, Lange RA, . Medical therapy of aortic aneurysms: a pathophysiology-based approach. Curr Vasc Pharmacol. 2011;9:572–84.
- Sorice GP, Folli F. A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes). Med Hypotheses. 2009;73:614–8.